CG Oncology, Inc. (CGON)
NASDAQ · Manufacturing · Biological products, (no diagnostic substances)
CGON price, last 12 months
Key stats
- Previous close
- $80.00
- Open
- $84.03
- Day range
- $79.96 – $84.22
- 52-week range
- $37.01 – $93.95
- Volume
- 2.5M
- Avg volume (20 days)
- 1.9M
- Market cap
- $6.6B
Performance
Technicals and fundamentals
About CG Oncology, Inc.
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NASDAQ
- Market cap
- $6.6B